Traders should prepare for potential volatility following the March 30 earnings release and conference call, particularly regarding clinical progress of ficerafusp alfa or cash runway. Recent insider selling may amplify downside sensitivity if results disappoint.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 23 $18.39entry
- T+1 · 8mo ago −1.25%α −0.90% · $18.16
- T+5 · 8mo ago +3.53%α +7.10% · $19.04
- T+20 · 7mo ago +25.67%α +18.25% · $23.11
- T+60 · 5mo ago +24.63%α +11.57% · $22.92
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Bicara Therapeutics announced it will report its Q4 and full-year 2025 financial results on March 30, 2026, along with a business update. The company will host a conference call to discuss the results, but no financial data or material updates were released in this press release.
Key Facts
- Bicara Therapeutics will report Q4 and full-year 2025 financial results on March 30, 2026, before market open.
- A conference call is scheduled for 8:30 a.m. ET on the same day to discuss results and business updates.
- No financial figures, guidance, or material operational updates were disclosed in this announcement.
- The company remains in clinical-stage development with ficerafusp alfa as its lead asset.
Financial Impact
No financial data disclosed, impact deferred until earnings release
Risk Factors
- No material information provided, event risk is forward-looking and contingent on upcoming earnings.
- Recent insider selling could signal lack of confidence ahead of the release.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260367 |
Track record
26 reports on BCAX
1 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +5.65% at T+20 after the Apr 15, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $9.98 Now $9.75 −2.30% settles Dec 8
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
- Nov 4, 202612d ago Press Release Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $16.42 to $8.89 Now $9.75 −40.62% ▼ −45.86% −44.52% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $17.29 to $9.13 Now $9.75 −43.61% ▼ −47.19% −44.73% vs SPY
- Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $22.78 to $18.35 Now $9.75 −57.20% ▼ −19.45% −18.89% vs SPY
- Aug 25, 202611w ago 8-K Neutral 2/10 Entry $24.73 to $19.78 Now $9.75 −60.57% ▼ −20.02% −20.24% vs SPY
- Aug 14, 202613w ago Press Release Neutral 2/10 Entry $24.28 to $23.20 Now $9.75 −59.84% ▼ −4.45% −2.46% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral Not scored Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers